Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
Journal Article (Journal Article)
INTRODUCTION: We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment. METHODS: Patients with unresectable MM and no symptomatic effusions were given dasatinib 70 mg twice daily as part of a 28-day cycle. We also measured plasma vascular endothelial growth factor and platelet-derived growth factor b and colony stimulating factor 1 (CSF-1) and mesothelin-related protein at baseline and during therapy. RESULTS: Forty-six patients were enrolled in this study. Fifty percent of the first 12 patients enrolled experienced ≥grade 3 treatment-related adverse events, and therefore, the starting dose was reduced to 50 mg twice daily. Grade 3 and 4 toxicities included fatigue (11%) and pleural effusion (9%). The overall disease control rate was 32.6%, and progression-free survival at 24 weeks was 23% (95% confidence interval: 13.5-40.0%). Survival was markedly longer in patients with lower pretreatment CSF-1 levels and in patients whose CSF-1 levels decreased from baseline during therapy. DISCUSSION: Single-agent dasatinib has no activity in MM and is associated with pulmonary toxicities that prohibit its use in an unselected MM population.
Full Text
Duke Authors
Cited Authors
- Dudek, AZ; Pang, H; Kratzke, RA; Otterson, GA; Hodgson, L; Vokes, EE; Kindler, HL; Cancer and Leukemia Group B,
Published Date
- April 2012
Published In
Volume / Issue
- 7 / 4
Start / End Page
- 755 - 759
PubMed ID
- 22425926
Pubmed Central ID
- PMC3308128
Electronic International Standard Serial Number (EISSN)
- 1556-1380
Digital Object Identifier (DOI)
- 10.1097/JTO.0b013e318248242c
Language
- eng
Conference Location
- United States